葛蘭素史克 (GSK) 2026 Q1 法說會逐字稿

內容摘要

  1. 摘要
    • Q1 營收成長 5%,達超過 76 億英鎊,核心營業利益成長 10%,EPS 成長 9%,現金流強勁。
    • 本季確認全年指引不變,預期 2026 年將持續獲利成長。
    • Shingrix、Specialty Medicines、HIV 產品線為主要成長動能,盤後市場反應未特別提及。
  2. 成長動能 & 風險
    • 成長動能:
      • Shingrix 疫苗銷售創新高,Q1 銷售超過 10 億英鎊,歐洲成長 51%,美國成長 12%。
      • Specialty Medicines(特藥)成長 14%,NUCALA COPD、Exdensur、Blenrep 等新產品推動增長。
      • HIV 產品組合(Dovato、Cabenuva、Apretude)雙位數成長,長效注射劑滲透率提升,Cabenuva Q1 成長 31%。
      • 腫瘤產品 Jemperli、Blenrep、ADC 管線推進,Jemperli Q1 成長 40%,多項新適應症臨床進展。
      • 積極推進後期研發管線,2025 年啟動 7 項三期試驗,2026 年預計再啟動 10 項。
    • 風險:
      • General Medicines(傳統藥品)Q1 下滑 6%,受老藥銷售下滑及美國 Medicare 共付額調整影響。
      • 歐洲、日本 Shingrix 疫苗進入高基期,未來成長比較基準變嚴峻。
      • HIV 產品面臨競爭者新口服長效方案挑戰,需持續維持產品差異化。
      • 部分新產品(如 Exdensur)在美國尚未取得 J-code,短期滲透受限。
  3. 核心 KPI / 事業群
    • Specialty Medicines:Q1 成長 14%,主因新產品與疫苗帶動。
    • Shingrix:Q1 銷售超過 10 億英鎊,年增 20%,歐洲成長 51%,美國成長 12%。
    • General Medicines:Q1 下滑 6%,主因老藥銷售下滑與美國共付額調整。
    • Jemperli(腫瘤):Q1 銷售 2.32 億英鎊,年增 40%。
    • NUCALA:COPD 新適應症推動美國市佔率達 45%,中國新病患滲透率約 50%。
    • HIV 事業群:Q1 銷售年增 10%,Cabenuva 成長 31%,Apretude 成長 44%。
  4. 財務預測
    • 2026 全年營收指引維持不變,預期持續獲利成長。
    • 毛利率 Q1 提升 110 個基點,受惠於產品組合優化(特藥與 Shingrix)。
    • 資本支出(CapEx)未揭露具體數字,但強調持續投資於研發與新產品推進。
  5. 法人 Q&A
    • Q: Exdensur 短效生物製劑高流失率的原因?J-code 取得後滲透展望?
      A: 主要因頻繁給藥導致順從性低,J-code 取得後預期美國市場進一步開放,目前僅 20% 商業病患可及,J-code 是主要障礙。
    • Q: Bepirovirsen(Bepi)商業化機會與定價策略?標籤適應症預期?
      A: 美中市場佔 70% 機會,美國聚焦高需求患者,中國聚焦前 15% 醫療機構,標籤細節未明,但臨床數據顯示 15-20% 功能性治癒具臨床意義。
    • Q: HIV 長效注射劑是否會受競爭對手每週口服新藥衝擊?
      A: 預期每週口服主要搶占每日口服市場,長效注射劑針對順從性差、擔心隱私的特定族群,影響有限。
    • Q: 加速研發管線推進的實際作法?
      A: 高層每兩週檢視臨床進度,直接與團隊溝通,靈活調整資源,強調快速決策與資源優先配置,創造更積極的組織文化。
    • Q: Shingrix 美國庫存變化、在中國的需求與未來展望?
      A: 美國 Q1 庫存增加屬正常範圍,PFS 上市帶來便利但未推升需求,中國實際接種量提升但短期銷售受現有庫存消化影響。

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • (audio in progress) Today's call will last approximately one hour with a presentation taking around 30 minutes and the remaining time for your questions. (Operator Instructions) Before we start, please turn to slide 3. This is the usual Safe Harbor statement. We will comment on our performance using constant exchange rates, or CER, unless otherwise stated. I'll now hand over to Luke.

    (音訊進行中)今天的電話會議約一小時,其中簡報約 30 分鐘,其餘時間留給各位提問。(接線員指示)開始之前,請翻到第 3 頁投影片。這是慣例的「安全港」聲明。除非另有說明,我們將以固定匯率(CER)來評論我們的表現。我現在把時間交給 Luke。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thank you, and welcome, everyone. Q1 performance was strong. Sales were up 5% to more than GBP7.6 billion. Growth was driven by Specialty Medicines, which were up 14% with vaccines also contributing particularly through strong Shingrix sales. Core operating profit grew 10% and EPS was up 9%. Cash generation was strong at GBP1.4 billion. And our Q1 dividend declared today is 17p. Looking forward, we expect another year of profitable growth reflected in the guidance confirmed today. Next slide, please.

    謝謝,歡迎各位。第一季表現強勁。銷售額成長 5%,超過 76 億英鎊。成長主要由專科藥品帶動,年增 14%,疫苗亦有貢獻,尤其是 Shingrix 銷售強勁。核心營業利益成長 10%,每股盈餘(EPS)成長 9%。現金創造力強勁,達 14 億英鎊。而我們今天宣告的第一季股利為每股 17 便士。展望未來,我們預期今年仍將是獲利成長的一年,並反映在今天確認的財測指引中。請看下一頁投影片。

  • In February, we set out our priorities to drive value. We've made a good start, but we've got more to do. In a minute, Nina will share progress on how we're delivering growth, including the launches of NUCALA COPD, Exdensur and Blenrep.

    2 月,我們闡述了推動價值的優先事項。我們已經有不錯的起步,但仍有更多工作要做。稍後 Nina 將分享我們如何推動成長的進展,包括 NUCALA COPD、Exdensur 與 Blenrep 的上市。

  • We're also assessing our pipeline on an ongoing basis, the aim being to progress high-potential assets more aggressively. As we identify differentiated profiles that fit an unmet need or address a gap in the market, we will then and are using scientific courage to make decisions in an accelerated way. This includes internal development as well as BD.

    我們也持續評估研發管線,目標是更積極地推進高潛力資產。當我們辨識出具差異化特徵、符合未被滿足需求或能補上市場缺口的產品輪廓時,我們將運用科學勇氣,以加速方式做出決策。這包括內部開發以及商務開發(BD)。

  • Now we're already making progress here with our assets in COPD, with our ADCs in oncology and with efimosfermin in MASH. Now we'll talk more about these and other high-value opportunities at Q2 results, and this will include an update on our HIV pipeline instead of an HIV-only event in June. Continuing to underpin these efforts to simplify how we work with greater pace, accountability and focus.

    目前我們在 COPD 資產、腫瘤領域的 ADC,以及 MASH 的 efimosfermin 上都已取得進展。我們將在第二季財報時更深入說明這些及其他高價值機會,並將以 HIV 管線更新取代 6 月僅聚焦 HIV 的單一活動。同時,我們也持續透過更高的速度、責任歸屬與聚焦,來簡化工作方式,以支撐上述努力。

  • I'll now hand over to Nina.

    我現在把時間交給 Nina。

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Thank you, Luke. Please turn to the next slide. Commercial momentum continued in Q1, driven by Shingrix and strong growth for key products across our specialty portfolio, which grew 14%. General Medicines was down 6% in the quarter, driven by declining sales of the older established portfolio. Strategy performance did not offset the broader portfolio decline as its growth in the US was limited by increasing co-pay requirements due to Medicare redesign. These are especially pronounced in the first quarter and are expected to be less relevant in the rest of the year.

    謝謝你,Luke。請翻到下一頁投影片。第一季商業動能延續,由 Shingrix 帶動,且我們專科產品組合中的關鍵產品強勁成長,使專科產品組合成長 14%。一般藥品本季下滑 6%,主要因較舊的既有產品組合銷售下滑。Strategy 的表現未能抵銷整體產品組合的下滑,因其在美國的成長受到 Medicare 改制導致自付額(co-pay)要求提高所限制。這些影響在第一季特別明顯,預期在今年其餘時間相關性會降低。

  • As Luke mentioned, we are focused on the products that drive the most venue, including new launches and growth contributors. Next slide, please. Shingrix was a key driver in Q1, setting a record for quarterly sales, delivering more than GBP1 billion, up 20%. Quarterly patterns continued with strong sales in Q1, driven by Europe, where sales were up 51%, following the uptick in national immunization programs and private market demand. In the US, where sales grew 12% driven by inventory movements, including the launch of the new pre-filled syringe.

    如 Luke 所提,我們聚焦於最能帶來營收的產品,包括新上市產品與成長貢獻者。請看下一頁投影片。Shingrix 是第一季的關鍵驅動因素,創下單季銷售紀錄,超過 10 億英鎊,年增 20%。季節性型態延續,第一季銷售強勁,主要由歐洲帶動;歐洲銷售年增 51%,反映國家免疫計畫與自費市場需求上升。在美國,銷售成長 12%,主要由庫存移動所帶動,包括新款預充式注射器的上市。

  • Moving forward, this year, we expect tougher comparators for Europe and Japan as most large immunization programs annualize. Further penetration opportunities remain with around 11% of the eligible population immunized in our top 10 markets outside the US. In oncology, Jemperli was again a key growth contributor, delivering GBP232 million, up 40%, driven by significant overall survival benefit in endometrial cancer.

    展望今年,隨著多數大型免疫計畫進入年化,我們預期歐洲與日本的比較基期將更具挑戰。在美國以外的前 10 大市場中,符合資格人口約僅 11% 已接種,仍有進一步滲透的機會。在腫瘤領域,Jemperli 再度成為關鍵成長貢獻者,營收 2.32 億英鎊,年增 40%,主要受子宮內膜癌顯著整體存活(OS)效益所帶動。

  • At the Society of Gynecological Oncology, we presented data from a four-year follow-up of the RUBY study, which showed an overall survival benefit over time, with 66% reduction in risk of death for patients with MMR MSI-high endometrial cancer. We look forward to the continued development of this medicine, including in rectal cancer with pivotal results from AZOR 1 in the second half of the year. Next slide, please.

    在婦科腫瘤學會(Society of Gynecological Oncology)上,我們發表了 RUBY 研究四年追蹤資料,顯示整體存活效益隨時間延續;對於 MMR MSI-high 子宮內膜癌患者,死亡風險降低 66%。我們期待持續推進此藥物的開發,包括直腸癌適應症;AZOR 1 的關鍵性結果預計於今年下半年公布。請看下一頁投影片。

  • NUCALA also delivered double-digit growth in Q1 following its expansion into COPD in the US last year. US growth was driven by a broad COPD label and the halo effect on other indications. Total brand new patient starts are now at their highest level, growing 65% year on year and we are accelerating momentum towards market leadership in COPD with around 45% of market share.

    NUCALA 在第一季也實現雙位數成長,延續去年在美國擴展至 COPD 適應症後的動能。美國的成長來自更廣泛的 COPD 標示,以及對其他適應症的光環效應(halo effect)。品牌新增病患起始治療人數目前達到歷史新高,年增 65%;我們正加速邁向 COPD 市場領導地位,目前市占約 45%。

  • COPD launches outside of the US, including Europe and China, have similar strong initial signals. For example, in China, we are already capturing around one in two new patients, representing a strong early launch in one of the largest markets globally with around 100 million people living with COPD.

    美國以外的 COPD 上市(包括歐洲與中國)也呈現同樣強勁的初期訊號。例如在中國,我們已取得約每兩位新增病患就有一位使用我們產品的比例;在全球最大市場之一、約有 1 億人罹患 COPD 的中國,這代表非常強勁的早期上市表現。

  • In the severe asthma space, our focus is now on Exdensur for which access in the US is still limited ahead of obtaining the J-code. Severe asthma is an area where significant opportunity remains as only 30% of eligible patients are receiving a biologic. The ultra long-acting dosing of Exdensur is a key value driver with around 97% of patients preferring six monthly dosing versus current options. This is also valued by prescribers as they understand that longer dosing intervals lead to greater adherence and therefore, better outcomes.

    在重度氣喘領域,我們目前聚焦於 Exdensur;在取得 J-code 之前,美國的給付可近性仍然受限。重度氣喘仍有顯著機會,因為符合資格的病患中僅 30% 正在接受生物製劑治療。Exdensur 的超長效給藥是關鍵價值驅動因素,約 97% 的病患偏好每 6 個月給藥一次,相較於目前選項。處方醫師也重視這一點,因為他們理解較長的給藥間隔可提升依從性,進而帶來更佳的治療結果。

  • Currently, 65% of patients discontinued their short-acting biologic in the first 12 months. The next critical milestone in the US is obtaining the J-code, which is expected early July, after which we expect access to be unrestricted. Next slide, please.

    目前有 65% 的病患在前 12 個月內停止使用其短效生物製劑。美國下一個關鍵里程碑是取得 J-code,預期在 7 月初完成;之後我們預期給付可近性將不再受限。請看下一頁投影片。

  • Moving to Blenrep, our community ready antibody drug conjugate for multiple myeloma. Simple administration and overall safety remains a differentiating factor as 70% of patients are in the community and accessibility to competitor options remains a challenge. In the US, we now have a majority of use in the community, an important indicator of success as academic centers tend to be the early adopters. Our data showing an extended benefit versus standard of care is resonating as is the simplicity of our REMS and coordination of eye care professionals.

    接著談 Blenrep,我們為多發性骨髓瘤打造、適用於社區端的抗體藥物複合體(ADC)。簡便的給藥方式與整體安全性仍是差異化因素;約 70% 的病患在社區端治療,而競品方案的可近性仍具挑戰。在美國,我們目前多數使用已在社區端,這是重要的成功指標,因為學術中心通常是早期採用者。我們顯示相較標準治療具延伸效益的數據引發共鳴;同時,我們的 REMS 流程簡化,以及眼科照護專業人員的協調安排也同樣受到肯定。

  • The number of US HCPs prescribing is growing with many repeating. Outside of the US, we have second-line approval in 19 markets, most recently in China, and we are progressing with launches in all major markets, including the UK, Germany, and Japan. And with that, I will hand over to Deborah.

    在美國,開立處方的醫療照護專業人員(HCP)人數持續增加,且許多人會重複開立。在美國以外,我們已在 19 個市場取得二線治療核准,最近的是中國;我們正推進所有主要市場的上市,包括英國、德國與日本。接下來,我把時間交給 Deborah。

  • Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

    Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

  • Thank you, Nina. I'm delighted to share another strong quarter of double-digit HIV sales growth of 10%, driven by our long-acting portfolio in Dovato. Demand and market share increased across all regions, most notably in the US, where sales grew at 15%, with treatment market share outpacing the competition. In Europe, we continue to capitalize on our long-standing market share leadership position.

    謝謝你,Nina。我很高興分享又一個強勁季度:HIV 銷售額以 10% 的雙位數成長,主要由我們在 Dovato 的長效產品組合所帶動。各地區的需求與市占率均提升,尤以美國最為顯著,銷售成長 15%,治療領域市占率增速超越競爭對手。在歐洲,我們持續把握我們長期以來的市占率領導地位。

  • Competitive execution is powering our portfolio transition to insty-led long-acting regimens, which consistently represent more than 70% of our total HIV growth and more than one-third of total US sales. With treatment accounting for around 90% of the total HIV market, we're delighted that Cabenuva grew 31% in Q1, fueled by patient demand.

    具競爭力的執行力正推動我們的產品組合轉向以 insty 為核心的長效療程,這些療程一貫貢獻我們 HIV 總成長的 70% 以上,並占美國總銷售額的三分之一以上。由於治療約占整體 HIV 市場的 90%,我們很高興 Cabenuva 在第一季成長 31%,主要受病患需求帶動。

  • We also saw accelerated switches from competitor products reaching 79% in the US this quarter. Apretude grew strongly at 44% in the quarter with standing impact from a competitor launch and reinforcing the importance of our more than 99% effective, highly tolerable, single-shot long-act injectable for HIV prevention. We're outpacing the field with our patient-centered pipeline built on a foundation of long-acting integrase inhibitors, the gold standard of HIV care.

    我們也看到本季在美國自競品加速轉換的比例提升至 79%。Apretude 本季強勁成長 44%,在競品上市帶來的持續影響下,更凸顯我們這款對 HIV 預防具 99% 以上有效性、耐受性佳、單次注射的長效注射劑的重要性。我們以以病患為中心的研發管線領先同業,該管線建立在長效整合酶抑制劑(HIV 照護的黃金標準)的基礎之上。

  • For 3 times yearly Cabenuva for treatment, our Quattro Phase III registrational study start is on track, and we expect to launch in 2028. Building on the success of 6 times yearly Cabenuva, the first and only complete long-acting injectable for HIV treatment, we believe this potential option will establish a new standard of care highly desired by patients and doctors whilst doubling provider administration capacity.

    針對每年 3 次給藥的 Cabenuva 治療方案,我們的 Quattro 第三期註冊性研究啟動進度如期,預期於 2028 年上市。在每年 6 次給藥的 Cabenuva(首個且唯一完整的 HIV 治療長效注射方案)成功基礎上,我們相信此潛在選項將建立病患與醫師高度期待的新照護標準,同時使醫療提供者的施打/管理量能倍增。

  • At 3 times yearly Apretude for PrEP is set to redefine HIV prevention once again, with registrational study data are anticipated in H2 2026 and an H1 2027 launch. We strongly believe this asset delivered through one injection with dosing frequency linked to routine sexually transmitted infection testing cycles has the optimal PrEP profile, better aligned to patient and HCP preference.

    每年 3 次給藥的 Apretude 用於 PrEP,將再次重新定義 HIV 預防;註冊性研究數據預計於 2026 年下半年公布,並於 2027 年上半年上市。我們堅信此資產以單次注射給藥,且給藥頻率與例行性性傳染病(STI)檢測週期相連結,具備最佳 PrEP 產品特性,更符合病患與醫療照護專業人員(HCP)的偏好。

  • At CROI, we shared data underscoring the strength of our pipeline assets, which we are evaluating for twice yearly long-acting injectable treatment and we remain on track to launch by the end of the decade. Data for VH184, our first third-generation entity with IP protection through to 2040, demonstrated potential for twice-yearly dosing and an enhanced in vitro resistance profile versus BIC.

    在 CROI 上,我們分享了凸顯研發管線資產實力的數據;我們正評估其用於每年 2 次給藥的長效注射治療,並仍按計畫於本十年末前上市。VH184(我們首個第三代實體,智慧財產權保護至 2040 年)的數據顯示具每年兩次給藥的潛力,且相較 BIC 具有更強的體外抗藥性特徵。

  • Our capsid inhibitor, VH-499 also showed promising potential for twice yearly dosing. This differentiated asset is highly potent and has a low risk of DDIs. And data for our Bnav latibabart showed high efficacy for 3 times yearly dosing when combined with monthly carategravir. We look forward to showing twice the early data later in 2026.

    我們的衣殼抑制劑 VH-499 也展現每年 2 次給藥的可期潛力。此差異化資產效力強,且藥物交互作用(DDIs)風險低。此外,我們的 Bnav latibabart 數據顯示,與每月一次 carategravir 合併使用時,每年 3 次給藥具有高療效。我們期待在 2026 年稍晚展示更進一步的早期數據。

  • As we advance our pipeline at pace, continue to deliver strong portfolio performance and prepare for our two upcoming 3 times yearly launches, we are well positioned to manage the dolutegravir loss of exclusivity and drive sustained long-term growth. And as Luke said earlier, we will share more about the HIV pipeline and Q2 results. I'll now hand over to Tony.

    隨著我們加速推進研發管線、持續交出強勁的產品組合表現,並為即將到來的兩項每年 3 次給藥上市做準備,我們已具備良好條件以因應 dolutegravir 專利到期(失去獨占性),並推動可持續的長期成長。此外,如 Luke 先前所說,我們將分享更多關於 HIV 研發管線與第二季業績。接下來我把時間交給 Tony。

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Thank you, Deborah. Next slide, please. In R&D, our top priority is to accelerate development to deliver new products to patients faster. And as you heard from Luke, we've been taking specific actions to advance our most exciting opportunities. In 2025, we started 7 Phase III trials with 10 more starting this year. We're making bold investment choices to drive value in the late-stage pipeline.

    謝謝你,Deborah。請看下一張投影片。在研發方面,我們的首要任務是加速開發,讓新產品更快送達病患。正如你從 Luke 那裡聽到的,我們已採取具體行動以推進最令人振奮的機會。在 2025 年,我們啟動了 7 項第三期試驗,今年還將再啟動 10 項。我們正做出大膽的投資選擇,以在後期研發管線中創造價值。

  • For example, our pivotal second-line trial in small cell lung cancer and BOLD 301 for, our B7-H3 ADC is recruiting well. We anticipate the expansion of the [Resurize] program with a number of Phase III trials planned, including in genitourinary cancers, which start later this year.

    例如,我們在小細胞肺癌的關鍵性二線試驗,以及針對 B7-H3 ADC 的 BOLD 301 試驗,招募進展良好。我們預期將擴大 [Resurize] 計畫,規劃多項第三期試驗,包括泌尿生殖系統癌症領域,並將於今年稍晚啟動。

  • Similarly, for Mo-Rez, our B7-H4 ADC, we've recruited more than 200 patients into Behold 1 and presented Phase I data for ovarian and endometrial cancers at SGO earlier this month. We have now initiated two Phase III studies with three more scheduled to start recruiting before the end of the year. More on Mo-Rez in a moment.

    同樣地,針對 Mo-Rez(我們的 B7-H4 ADC),我們已在 Behold 1 納入超過 200 名病患,並於本月稍早在 SGO 發表卵巢癌與子宮內膜癌的第一期數據。我們現已啟動兩項第三期研究,另有三項預計在年底前開始招募。稍後我會再談 Mo-Rez。

  • StrateGIST 3, the first Phase III trial for of velzatinib in second-line GIST started recruiting at the end of last year, less than 12 months after acquiring the asset. A second Phase III trial in a first-line patient population will start in the second half. Elsewhere in oncology, at ASCO this year, we have five oral abstracts accepted for presentation, including data from the DREAMM 9 study. which will inform dosing strategy for newly diagnosed multiple myeloma patients. This schedule will be employed in Dreamm 10 and in PrECOG, an upcoming cooperative group study.

    StrateGIST 3 作為 velzatinib 用於二線 GIST 的首項第三期試驗,於去年底開始招募,距離取得該資產尚未滿 12 個月。第二項針對一線病患族群的第三期試驗將於下半年啟動。在腫瘤領域的其他方面,今年 ASCO 我們有五篇口頭摘要獲選發表,其中包括 DREAMM 9 研究數據,將用以制定新診斷多發性骨髓瘤病患的劑量策略。此給藥時程將應用於 Dreamm 10 以及即將進行的合作組研究 PrECOG。

  • In RI and I, we acquired efimosfermin in May 2025, where our priority was to advance this asset into Phase II, our two pivotal studies started last year. So NII and 2 in F2, F3 stage MASH and are recruiting well with the Nebula program for Advanced MASH on track to start later this year.

    在 RI 與 I 領域,我們於 2025 年 5 月取得 efimosfermin;我們的優先事項是將此資產推進至第二期,而我們的兩項關鍵性研究已於去年啟動。因此,NII 與 2 在 F2、F3 期 MASH 的研究招募進展良好,而針對進展期 MASH 的 Nebula 計畫也按進度預計於今年稍晚啟動。

  • Moving to pivotal readouts. We reported positive headline results for Bepi during the quarter, which I will cover shortly, and we have four further Phase III readouts to come in the second half for Jemperli in rectal cancer, camlipixant in refractory chronic cough, Exdensur in EGPA and our three times yearly preexposure prophylaxis for HIV.

    接著談關鍵性讀出。本季我們公布了 Bepi 的正面重點結果,我稍後會說明;此外,下半年還將有另外四項第三期讀出,包括:Jemperli 用於直腸癌、camlipixant 用於難治性慢性咳嗽、Exdensur 用於 EGPA,以及我們每年 3 次給藥的 HIV 暴露前預防。

  • Lastly, our business development activities continue to complement and enhance our portfolio. In Q1, we announced two acquisitions: ozureprubart in food allergies and HS235 in pulmonary hypertension. Both have clinically validated MOAs and the potential to be best-in-class. These assets build on GSK's existing expertise in respiratory and inflammation. Next slide, please.

    最後,我們的商業發展活動持續補強並提升我們的產品組合。第一季我們宣布兩項收購:用於食物過敏的 ozureprubart,以及用於肺動脈高壓的 HS235。兩者皆具臨床驗證的作用機轉(MOA),並有潛力成為同類最佳。這些資產建立在 GSK 既有的呼吸與發炎領域專業之上。請看下一張投影片。

  • As I briefly mentioned, we've announced positive Phase III data for our functional cure for chronic hepatitis B, efimosfermin . The Bell 1 and 2 data show a statistically significant and clinically meaningful increase in the rate of functional cure and the full data will be presented at EASL in May. This outcome is important for patients because chronic hepatitis B infection is associated with high rates of liver cancer and an increase in all-cause mortality.

    如我先前簡要提到的,我們已公布針對慢性 B 型肝炎的功能性治癒療法 efimosfermin 的正面第三期數據。Bell 1 與 2 的數據顯示,功能性治癒率在統計上顯著且具臨床意義地提升,完整數據將於 5 月在 EASL 發表。此結果對病患很重要,因為慢性 B 型肝炎感染與高比例肝癌及全因死亡率上升相關。

  • A recent US epidemiology study in hepatitis B patients showed that loss of surface antigen was associated with an 89% reduced risk of hepatocellular carcinoma and a 62% reduced risk in all-cause mortality. Regulatory reviews for bepi are progressing well. Bepi now has breakthrough designation in the US and a PDUFA date of the October and has been accepted for priority review in China. Commercial preparations are underway in these two markets, which represent around two-thirds of the commercial opportunity globally.

    近期一項美國針對 B 型肝炎病患的流行病學研究顯示,表面抗原消失與肝細胞癌風險降低 89% 以及全因死亡風險降低 62% 相關。bepi 的法規審查進展順利。bepi 目前在美國已獲突破性療法認定,PDUFA 日期為 10 月,並已在中國獲受理優先審查。我們正於這兩個市場進行商業化準備,兩者合計約占全球商業機會的三分之二。

  • Next slide, please. Turning to pipeline progress in oncology and our global Behold 1 Phase I study of Mo-Rez in advanced endometrial cancer and platinum-resistant ovarian cancer. Mo-Rez is a B7-H4 targeting ADC, and B7-H4 is overexpressed in many gynecological tumors with low expression in normal tissues. In this dose escalation study, Mo-Rez showed encouraging antitumor activity. At the highest doses confirmed ORR was 62% in Proc and 67% in advanced DC, with responses observed regardless of B7-H4 expression.

    下一張投影片,謝謝。接著談腫瘤領域的研發管線進展,以及我們全球 Behold 1 第一階段(Phase I)研究中,Mo-Rez 用於晚期子宮內膜癌與鉑類抗藥性卵巢癌的進展。Mo-Rez 是一款以 B7-H4 為標的的 ADC,而 B7-H4 在許多婦科腫瘤中呈現過度表現,在正常組織中的表現則偏低。在這項劑量遞增研究中,Mo-Rez 顯示出令人鼓舞的抗腫瘤活性。在最高劑量下,經確認的 ORR 在 Proc 為 62%,在晚期 DC 為 67%,且不論 B7-H4 表現量高低皆觀察到反應。

  • Durability of response data were also encouraging. In the highest dose prop cohort, only 1 patient from 21 progressed within six months. Mo-Rez was generally well tolerated with low discontinuation rates and incidence of ILD. Only about 3% of patients reported mild to moderate pneumonitis. Based on these exciting data and additional data from our partner, Hansoh, we plan to start five pivotal trials this year in EC and OC. Next slide, please.

    反應持久性(durability of response)的數據同樣令人鼓舞。在最高劑量的 prop 隊列中,21 位患者中僅 1 位在六個月內出現疾病進展。Mo-Rez 整體耐受性良好,停藥率與 ILD 發生率均偏低。僅約 3% 的患者回報輕至中度的肺炎(pneumonitis)。基於這些令人振奮的數據,以及我們合作夥伴 Hansoh 提供的額外資料,我們計畫今年在 EC 與 OC 啟動五項關鍵性試驗(pivotal trials)。下一張投影片,謝謝。

  • Elsewhere in oncology portfolio, our partner, Hansoh, presented new [RisRes] data at a plan recession at AACR early this month. The data are from a Hansoh-sponsored Phase I study called ARTEMIS-101 which looked at rises in combination with PD-L1 in 40 patients with second-line plus nonsquamous non-small cell lung cancer. The data show a 47% ORR with a median PFS of 14 months. The combination was generally well tolerated with grade three adverse events, mostly reflecting hematological toxicity consistent with similar ADCs.

    在腫瘤產品組合的其他部分,我們的合作夥伴 Hansoh 於本月初在 AACR 的計畫口頭報告中發表了新的 [RisRes] 數據。這些數據來自 Hansoh 贊助的一項第一期研究 ARTEMIS-101,評估 rises 與 PD-L1 聯合用藥,納入 40 位二線及以上的非鱗狀非小細胞肺癌患者。數據顯示 ORR 為 47%,中位數 PFS 為 14 個月。該聯合療法整體耐受性良好;三級不良事件多反映血液學毒性,與同類 ADC 的表現一致。

  • Four cases of treatment-related ILD were reported in the study, and these were grade 1 or 2. These exciting data used to support the start of a Phase III non-small cell lung cancer trial in China and we plan to initiate a Phase II study for rises in combination with Jemperli in a global population. Next slide, please.

    研究中回報了 4 例與治療相關的 ILD,且均為 1 級或 2 級。這些令人振奮的數據用以支持在中國啟動一項非小細胞肺癌的第三期(Phase III)試驗,我們也計畫在全球人群中啟動 rises 與 Jemperli 聯合用藥的第二期(Phase II)研究。下一張投影片,謝謝。

  • As I mentioned, accessing innovation through BD continues to be key to acceleration and growth. In February, we announced an agreement to acquire 35Pharma. Their lead asset is HS235, a potential best-in-class clinically validated activin signaling inhibitor to treat Group I and Group II pulmonary hypertension.

    如我先前提到,透過 BD 取得創新仍是加速與成長的關鍵。2 月,我們宣布達成收購 35Pharma 的協議。其主力資產為 HS235,一款具臨床驗證、潛在同類最佳(best-in-class)的 activin 訊號抑制劑,用於治療第一組與第二組肺高壓。

  • HS235 is currently in Phase I development. PH is a progressive and life-limiting disease with high symptom burden and sub-optimal patient outcomes. Five-year survival rates are around 50%. This is an underserved area in cardiopulmonary medicine with few available disease-modifying treatment options and significant growth potential.

    HS235 目前處於第一期(Phase I)開發階段。肺高壓(PH)是一種進行性且限制生命的疾病,症狀負擔高,患者預後不佳。五年存活率約為 50%。這是心肺醫學中一個未被充分滿足的領域,可用的疾病修飾治療選項有限,且具顯著成長潛力。

  • HS235 has the potential to treat patients while reducing bleeding-related side effects and providing metabolic benefits versus existing therapies, entering cardiopulmonary disease complements GSK's commercial footprint, providing new opportunities to achieve broader coverage across the multiple chronic diseases which affect the lung, liver, and kidney. We successfully closed the transaction on the April 15 and look forward to moving this asset into Phase II development at pace. I'll now hand over to Julie.

    相較於現有療法,HS235 具備在治療患者的同時降低出血相關副作用並提供代謝效益的潛力;切入心肺疾病也可補強 GSK 的商業版圖,帶來新的機會,以在影響肺、肝與腎的多種慢性疾病上達成更廣泛的覆蓋。我們已於 4 月 15 日順利完成交易交割,並期待以加速節奏推進該資產進入第二期(Phase II)開發。接下來我把時間交給 Julie。

  • Julie Brown - Chief Financial Officer, Executive Director

    Julie Brown - Chief Financial Officer, Executive Director

  • Thank you, Tony, and good afternoon, everyone. Next slide, please. Starting with the income statement for the quarter. Sales grew 5% and gross margin improved 110 basis points due to the growth of Specialty and Shingrix benefiting product mix this quarter.

    謝謝你,Tony,各位下午好。下一張投影片,謝謝。先從本季損益表開始。銷售額成長 5%,毛利率提升 110 個基點,主要受惠於專科(Specialty)與 Shingrix 的成長,帶動本季產品組合改善。

  • SG&A declined 2%, helped by positive IP settlements. On an underlying basis, SG&A grew 2%, demonstrating P&L leverage and continued productivity improvements. R&D spend was driven by accelerated investment in the pipeline, including the efimosfermin and dasatinib pivotal trials. We will continue to invest in R&D as we initiate multiple late-stage trials across our Specialty portfolio. Royalties benefited from Abrazo and commonality income streams. And operating profit grew 10% in the quarter, including the legal settlements, which were worth 3 percentage points. EPS grew 9%, impacted by a higher tax rate and increased finance expenses, partially offset by the benefits of the share buyback. Next slide, please.

    SG&A 下降 2%,主要受惠於正向的智慧財產(IP)和解。以基礎(underlying)口徑來看,SG&A 成長 2%,顯示損益表槓桿效應與持續的生產力提升。研發(R&D)支出則由加速投資研發管線所驅動,包括 efimosfermin 與 dasatinib 的關鍵性試驗。隨著我們在專科產品組合中啟動多項後期試驗,我們將持續投資研發。權利金(Royalties)受惠於 Abrazo 與 commonality 的收入來源。本季營業利益成長 10%,其中包含法律和解,貢獻約 3 個百分點。EPS 成長 9%,但受到較高稅率與財務費用增加的影響,部分由庫藏股回購帶來的效益所抵銷。下一張投影片,謝謝。

  • Turning to the cash flow and capital allocation. Cash generation was strong, albeit partially masked by the impact of adverse currency. CGFO was slightly ahead of last year, with increased operating profit and IP income from the CureVac settlement, broadly offset by the timing of trade payables. Free cash flow benefited from the $250 million special dividend received as part of the changes to the Vive shareholding structure.

    接著看現金流與資本配置。現金創造力強勁,但部分被不利匯率影響所掩蓋。CGFO 略高於去年,營業利益增加與 CureVac 和解帶來的 IP 收入,整體上大致被應付帳款時點因素所抵銷。自由現金流受惠於因 ViiV 持股架構調整而收到的 2.5 億美元特別股利。

  • Looking ahead, we remain on track to reach our target of more than GBP10 billion of CGFO, with cash flows weighted as now towards half two. Next slide, please. Strong cash generation and strategic actions have supported our capital allocation priorities with net debt at 1.4 times EBITDA. Investments in BD primarily comprised the GBP1.4 billion upfront to acquire RAPT Therapeutics. Shareholder returns totaled over GBP0.9 billion and the share buyback is on track to be completed at the half year.

    展望未來,我們仍按計畫達成 CGFO 超過 100 億英鎊的目標,且現金流將如目前所見更偏向下半年。下一張投影片,謝謝。強勁的現金創造與策略性行動支持了我們的資本配置優先事項,淨負債為 EBITDA 的 1.4 倍。BD 投資主要包括為收購 RAPT Therapeutics 支付的 14 億英鎊預付款(upfront)。股東回饋合計超過 9 億英鎊,且股票回購預計將於上半年完成。

  • In the second quarter, we expect to have an outflow of $950 million for the acquisition of 35Pharma. And we are optimizing the portfolio and generating cash income to reinvest in the business, including the ViiV special dividend, the divestment of the Rockville manufacturing site, and the out-licensing of linerixibat. These transactions will positively impact net debt by $1.2 billion in the first half, including Linorexibat completed in Q2, yielding $400 million. Next slide, please.

    在第二季,我們預期將有 9.5 億美元的現金流出,用於收購 35Pharma。同時,我們正優化產品組合並創造現金收入以再投資於業務,包括 ViiV 特別股利、Rockville 製造基地的處分,以及 linerixibat 的對外授權(out-licensing)。這些交易將在上半年對淨負債帶來 12 億美元的正面影響,其中包括於第二季完成的 Linorexibat,帶來 4 億美元。下一張投影片,謝謝。

  • Looking to the full year, we are confirming the guidance shared in February. In terms of phasing, we remain on track for our full year product group guidance with a few things to note. First, vaccines growth in Q1 benefited from the US Shingrix prefilled syringe stocking. And from Q2 onwards, we will begin to annualize the publicly funded programs in Japan and certainly new countries last year.

    就全年而言,我們確認 2 月所分享的財測指引。在時點分布方面,我們仍按計畫達成全年產品組別指引,但有幾點需要注意。第一,第一季疫苗成長受惠於美國 Shingrix 預充式注射器的備貨。自第二季起,我們將開始把日本的公費計畫,以及去年新增國家的相關計畫進行年化比較。

  • Second, Gen Med growth is expected to be half two weighted. Notably, in the second quarter, Trelegy has a tough comparator due to prior year true-up benefits, and international markets are expected to remain challenging. We still expect operating profit growth to be predominantly half two weighted given the phasing of productivity benefits. And you'll recall, we will also be comping the RSV IP settlement received in Q2 last year. Next slide, please. Turning to our road map, which shows our commitment to deliver. We've made a strong start to the year in terms of execution, pipeline, and isciplined capital allocation, including the acquisition of two new high-potential assets.

    第二,Gen Med 的成長預期將偏向下半年。值得注意的是,第二季 Trelegy 因去年有一次性調整(true-up)效益而面臨較高比較基期,且國際市場預期仍將具挑戰。由於生產力效益的時點分布,我們仍預期營業利益成長將主要集中在下半年。此外,各位也會記得,我們在比較基期上也將面對去年第二季收到的 RSV IP 和解款。下一張投影片,謝謝。接著看我們的路線圖,展現我們對交付成果的承諾。我們在執行、研發管線與紀律性的資本配置方面,已為今年打下強勁開局,其中包括收購兩項具高潛力的新資產。

  • And with that, I am happy to hand back to Luke.

    說到這裡,我很高興把時間交還給 Luke。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Julie. In summary, we've made a good start to 2026. We're completely focused on managing the business to drive top-line growth and accelerate the pipeline, and we're committed to taking the critical steps needed to do this. We look forward to updating you more at our Q2 results in July. Thank you, and we'll now move to Q&A.

    謝謝,Julie。總結來說,我們在 2026 年有一個良好的開局。我們完全專注於管理業務,以推動營收成長並加速產品管線的推進,而且我們承諾採取達成這一目標所需的關鍵步驟。我們期待在 7 月公布第二季(Q2)業績時,向各位提供更多更新。謝謝,接下來我們進入問答環節。

  • Operator

    Operator

  • (Operator Instructions) First question comes from Kerry Holford.

    (接線員指示)第一個問題來自 Kerry Holford。

  • Unidentified Participant

    Unidentified Participant

  • Nina, please, one for you on Exdensur. On the slide you showed, you talked of around 65% of patients discontinuing short-acting biologics in respiratory within the first 12 months. So that seems higher than I might have thought. So I'm just interested to see if you've got more detail on why those patients are discontinuing? Does it relate to efficacy, safety, perhaps compliance difficulties relating to the monthly dosing? And then also what happens to those patients you discontinue, do you see them return and keep?

    Nina,想請教你一題關於 Exdensur。你在投影片上提到,在呼吸領域,約有 65% 的病患在前 12 個月內停止使用短效型生物製劑。這比例看起來比我原先預期的更高。我想了解你們是否有更多細節,說明這些病患為何停藥?是否與療效、安全性有關,或是與每月給藥相關的依從性困難?另外,那些停藥的病患後續會怎麼樣,你們是否看到他們回流並持續使用?

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Yes, sure. So Kerry, there are a number of reasons, but one of them and the significant one is compliance and the requirement for frequent dosing, which, as you know, varies from every two weeks to every four weeks for short acting. What happens to those patients, they will usually go back to inhaled medicines and some of them eventually will might come back again to a biologic I'm not sure what that proportion would be, but we usually characterize patients who have not been on a biologic for 12 months as new to biologic. But in a nutshell, a number of reasons, compliance being the really significant part of that.

    好的,當然。Kerry,原因有好幾個,其中一個且相當重要的是依從性,以及需要頻繁給藥的要求;如你所知,短效型的給藥頻率從每兩週到每四週不等。這些病患通常會回到吸入型藥物治療,其中有些人最終可能會再回到生物製劑;我不確定那個比例是多少,但我們通常會把已經 12 個月未使用生物製劑的病患,視為生物製劑新用戶。總之,原因很多,而依從性確實是其中最關鍵的一部分。

  • Operator

    Operator

  • Next question comes from Zain Ebrahim.

    下一個問題來自 Zain Ebrahim。

  • Zain Ebrahim - Analyst

    Zain Ebrahim - Analyst

  • Zain Ebrahim, JPMorgan. My question is on the strategy update that you expected to provide with the Q2 results . What could we expect to learn from you there in terms of your pipeline, how much emphasis should we expect from you on the midterm outlook to 2021 versus the longer-term outlook beyond 2031? And you made comments in Q1 about -- or Q4 even about the HIV business, and we've seen the monthly data since then. So could we still expect you to provide an outlook on how HIV might look in 2031?

    我是 JPMorgan 的 Zain Ebrahim。我的問題是關於你們預計在第二季(Q2)業績時提供的策略更新。就產品管線而言,我們可以期待從你們那裡了解到什麼?你們會把重點放在到 2031 年的中期展望,還是更長期、2031 年之後的展望?另外,你們在第一季(Q1)—甚至第四季(Q4)—曾對 HIV 業務發表評論,而我們也看到此後的月度數據。那麼,我們是否仍可期待你們提供 2031 年 HIV 可能呈現樣貌的展望?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Sure, Zain. I mean the -- we've obviously been very busy. There's been a very aggressive prosecution of opportunities to accelerate the late-stage pipeline. I direct you to the bottom right-hand corner on slide 13 and Tony's presentation, I think it's a good summary. And so yes, I think the timing made sense at that point to take more time to lay out the whole portfolio both in terms of things that we can do that have a midterm impact as well as longer-term impact and HIV will be embedded within that because again, we want people to look at the total business in aggregate and the progress that we're making there. So yes, I think that's a good summary at this point.

    當然,Zain。我的意思是——我們顯然一直非常忙碌。我們正以非常積極的方式推進各項機會,以加速後期產品管線。我請你參考 Tony 簡報第 13 張投影片右下角,我認為那是一個很好的摘要。因此是的,我認為在那個時間點,多花一些時間把整體產品組合完整地鋪陳出來是合理的,包含我們能做的、對中期以及長期都有影響的事項;HIV 也會包含在其中,因為我們希望大家以整體角度來看整個業務,以及我們在其中取得的進展。所以是的,我認為目前這樣的總結是恰當的。

  • Operator

    Operator

  • Next question comes from Graham Parry.

    下一個問題來自 Graham Parry。

  • Unidentified Participant

    Unidentified Participant

  • A question on Bepirovirsen. The PDUFA is coming in October, you got data coming at EASL. Perhaps you could just outline the opportunity you see for the molecule. Do you see it more as a high-priced US-centric asset or lower-priced, higher-volume asset across China? And can you achieve differential pricing across the regions? And on label expectation, are you expecting a label for the broad population or just the low hepatitis B surface antigen group? I think it's less than 1,000 international units per mil population that you flagged in the headline press release has better functional cure rates.

    我有一題關於 Bepirovirsen。PDUFA 將在 10 月到期,你們也會在 EASL 公布數據。或許你們可以概述一下你們認為這個分子的機會在哪裡。你們認為它更像是高定價、以美國為中心的資產,還是低定價、在中國以高量取勝的資產?你們能否在不同地區實現差異化定價?另外就適應症標籤的預期而言,你們預期會是涵蓋廣泛族群,還是僅限於低乙肝表面抗原(HBsAg)族群?我記得你們在新聞稿標題中提到,低於每毫升 1,000 國際單位的族群具有較佳的功能性治癒率。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Nina, do you want to -- or maybe, Tony, if you go into the data is all reg pathway and then we can get.

    Nina,你要不要——或者 Tony,如果你先談一下數據與整個法規路徑,然後我們再接著回答。

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Yes. So Graham, I'm not going to get into the details of the label, but just to remind you that the BWI and the 2 studies were chosen from the population that had a surface antigen level of 3,000 or less. So I think it's important to understand that complete well population. We'll cover that broader group. That's about 65% of the ITT population. The 1,000 group is about 45%. And as I've said in the past, the data we have suggest that there is a relationship between surface antigen level and outcome where you shouldn't interpret that as being a linear one.

    好的。Graham,我不會深入談標籤細節,但提醒一下,BWI 與那兩項研究選取的族群,其表面抗原水準是 3,000 或以下。所以我認為理解那個完整的族群非常重要。我們會涵蓋那個較廣的族群。那大約占 ITT 族群的 65%。而 1,000 的那一組大約是 45%。正如我過去所說,我們的數據顯示表面抗原水準與結果之間存在關聯,但不應將其解讀為線性關係。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yeah. And I mean, the other thing I'd add before Nina, if you want to add anything else, if you look, the 1,000 cutoff, surface antigen is about 45% of the population. US patients, the bulk of them are vertically infected, it's around 1.2 million. Of home, about just over 300,000 are on treatment today. Europe is a little more in terms of 1.4. And yeah, about 200,000 on treatment.

    是的。另外我想補充的是,若看 1,000 這個切點,表面抗原低於該值的約占族群 45%。美國病患多數是垂直感染,總數約 120 萬人。其中目前接受治療的略高於 30 萬人。歐洲在總量上略多一些,約 140 萬人;是的,目前約 20 萬人在治療中。

  • China is much larger in terms of 57 million sort of infected, but only 16 million are diagnosed and they have much greater use of interferon there. So yeah, I mean, the treated population is around 10 million. But what we're being thoughtful about is particularly the strategy in China, I think the strategy in the US and Europe is very clear. What we're reflecting on very actively is the pathway to launch in China. Nina, anything you want to add on that?

    中國在規模上大得多,約有 5,700 萬感染者,但只有 1,600 萬被診斷出來,而且那裡使用干擾素的比例高得多。所以是的,接受治療的人口大約是 1,000 萬。但我們正在審慎思考的,特別是中國的策略;我認為美國與歐洲的策略非常清楚。我們目前非常積極地在評估的是在中國上市的路徑。Nina,你還想補充什麼嗎?

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Yes. Maybe I will say. So the way we think about it is the way we see the opportunity, about 70% of the opportunity are between US and China. As Luke mentioned, US in hundreds of thousands in treated patients diagnosed are probably only about 1/3 of the total. And the way we see the opportunity now reflects really those patients who are currently treated. Those are patients who had high desire to be treated. And again, still in the US, US market is highly focused on relatively limited areas. So there are about five states in the US where Hep B is prevalent and treated, and these are unsurprisingly states that have relatively high number of immigrants from Asian and African countries.

    是的。也許我可以說一下。我們的看法是,就機會而言,大約 70% 的機會在美國與中國之間。如 Luke 提到,美國已診斷且接受治療的病患是數十萬人,但可能只占總數的大約三分之一。而我們目前對機會的判斷,主要反映的是那些目前正在接受治療的病患。這些病患有很強的治療意願。而且在美國,美國市場仍高度集中在相對有限的區域。美國大約有五個州乙肝較為盛行且治療較多;不意外地,這些州有相對較多來自亞洲與非洲國家的移民。

  • And those who are treated clearly access to treatment. So this is unlike Hep C. This is patient population that have insurance that have needs to be treated and then have desire to be treated. So that gives you a little bit a sense about where we are going and how we are going to approach it. It's quite focused area geographically. In China, about 70% of patients or patient potential market potential is in about top 15% of the accounts. So again, a very focused approach in a country where Hepatitis B is considered to some extent, to be a stigma with very high desire of treatment. That's why you have very high use of interferon, which is not a pleasant drug to be on for a very long time.

    而接受治療的人顯然具備治療可近性。因此這不同於丙肝(Hep C)。這是一個有保險、需要治療、且也有治療意願的病患族群。這能讓你大致理解我們的方向,以及我們將如何切入。在地理上會是相當聚焦的區域。在中國,約 70% 的病患(或潛在市場)集中在前 15% 的醫療機構帳戶中。因此同樣會採取非常聚焦的方式;在一個乙型肝炎在某種程度上被視為帶有汙名、且治療意願很高的國家。這也是為什麼那裡干擾素的使用率很高——而那並不是一種適合長期使用、體驗愉快的藥物。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • One more. Great one final point to finish off with. Remember, we said before that 15% to 20% functional cure across the population would be considered clinically meaningful, and that's reflected in the expedited designations that we're getting, including the most recent one, obviously, from the FDA.

    再補充一點。很好,最後再用一個重點作結。請記得,我們先前說過,若在整體族群中達到 15% 到 20% 的功能性治癒,將被視為具有臨床意義,而這也反映在我們所獲得的加速審查/快速通道等指定資格上,包括最近一次,顯然是來自 FDA 的。

  • Operator

    Operator

  • Next question comes from Rajan Sharma.

    下一個問題來自 Rajan Sharma。

  • Unidentified Participant

    Unidentified Participant

  • Just one on HIV. And obviously, we're expecting some competitor data for once-weekly oral treatment option this year. Some of the physician feedback that we've had to suggest that will -- there'll be strong demand for that. So Deb, I just wanted to understand how you think about that from a ViiV perspective, in terms of near-term impact? And then ultimately, do you think that, that is restrictive to ultra long-acting injectables?

    我只有一個關於 HIV 的問題。很明顯,我們預期今年會看到競品每週一次口服治療選項的一些數據。我們收到的一些醫師回饋顯示——對此會有很強的需求。所以 Deb,我想了解從 ViiV 的角度,你如何看待這件事對短期影響?以及最終你是否認為,這會限制超長效注射劑的發展?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Do you want to take that?

    你要回答這題嗎?

  • Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

    Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

  • Yes. Thanks, Rajan. So in terms of the once-weekly oral that's being launched for next year and data this year, I think, is islatravir plus lenacapavir. So I think what we have communicated is critical to successful regimens, their robust in HIVs having an integrated inhibitor at the core. Today, about 85% of people globally or an integrated inhibitor-based regimen. And certainly, where we've got two-drug regimens such as Dovato having integrated at the core, I think it's pretty critical.

    好的。謝謝你,Rajan。就明年將推出、而今年會有數據的每週一次口服方案而言,我認為是 islatravir 加上 lenacapavir。我想我們一直傳達的是:成功的治療組合很關鍵的一點,是在 HIV 治療中以整合酶抑制劑作為核心。目前全球約 85% 的患者使用的是以整合酶抑制劑為基礎的治療方案。而且,當我們有像 Dovato 這樣的雙藥方案、以整合酶抑制劑為核心時,我認為這點相當關鍵。

  • So I think it will be interesting to see the data, but I think me, when you get to really outstanding with oral, it would be with an enterprise at the core. And then of course, there are -- let's see where we are with islatravir, obviously, we've seen challenges with islatravir higher doses in terms of depletion of CD4 counts. And I think physicians have questions about longer term, will that manifest itself even at a lower dose if somebody is on this medicine for a long time.

    所以我認為看到數據會很有意思,但在我看來,若要把口服做到真正非常出色,會是以整合酶抑制劑作為核心。當然,另外還有——我們也要看看 islatravir 的進展;很明顯,我們已看到 islatravir 在較高劑量時,會在 CD4 計數耗竭方面遇到挑戰。我想醫師也會對長期使用提出疑問:如果有人長期服用這個藥物,即使在較低劑量下,是否仍會出現這種情況。

  • However, undoubtedly, there will be some uptake. And all the research that we've done says that the weekly almost cannibalizes the daily orals, actually, our research shows that it doesn't impact long-acting injectables because that is a very specific patient segment where you've got people who struggle to adhere who really feel very stigmatized by taking a tablet every day or really worried about people discovery status as well as obviously the benefit of directly observed therapy. So I think the long-acting injectable segment won't be impacted by the once weekly, but the daily orals are most likely to be.

    不過,毫無疑問會有一定程度的採用。而我們做的所有研究都顯示,每週一次幾乎會蠶食每日口服;事實上,我們的研究顯示它不會影響長效注射劑,因為那是非常特定的病人族群:有些人難以遵從用藥、每天吞藥會感到高度汙名化,或非常擔心他人發現其感染狀態;此外,當然也有直接觀察治療(DOT)的好處。所以我認為長效注射劑的區隔不會受到每週一次方案影響,但每日口服很可能會。

  • Operator

    Operator

  • Next question comes from Sachin Jain.

    下一個問題來自 Sachin Jain。

  • Unidentified Participant

    Unidentified Participant

  • Two quick questions, please. One on [KALMY], sure expect this level of excitement headed into KALM-2 with KALM-1 in-house, I guess? And then secondly, on HIV, one of your key narratives obviously, Luke and R&D team is acceleration of key assets. Given the importance of long-acting injectable, I just wonder is there any scope to shorten or skip the Phase II work around Q6M combos and accelerate Phase III such launches are ahead of, I guess, a 2030-31 timeline?

    請問兩個簡短問題。第一個關於 [KALMY]:在 KALM-1 數據已在內部掌握的情況下,你們是否預期在進入 KALM-2 前會有這種程度的興奮/期待?第二個關於 HIV:你們的關鍵敘事之一(Luke 與研發團隊)顯然是加速關鍵資產。鑑於長效注射劑的重要性,我想知道是否有任何空間可以縮短或跳過 Q6M 組合的第二期工作、並加速進入第三期,讓上市時間早於我想大概是 2030-31 的時程?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Sure, Sachin, I think you get a pass on two questions. I think you asked a question last time. So Deborah, a super quick acceleration options and then Tony on KALMY [biz].

    好的,Sachin,我想你可以問兩題。我記得你上次也問了問題。所以 Deborah,先非常快速談一下加速的選項,然後 Tony 再談 KALMY [業務]。

  • Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

    Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

  • Actually, we are looking to accelerate through execution and the delivery of our Q6M or twice yearly in treatment and in PrEP. The FDA will not allow us or anybody else actually to skip the Phase II part of the development journey. We have to demonstrate the level of efficacy safety as well as the appropriate partner for our Q6M. So we'll go through the journey of development to demonstrate all of that, but we're in dialogue with the FDA and there's now where we can skip the Phase II.

    其實,我們正透過執行與交付來加速我們的 Q6M(每六個月一次)或一年兩次的治療與 PrEP。FDA 不會允許我們——或任何其他人——跳過研發流程中的第二期。我們必須證明療效與安全性的水準,以及為我們的 Q6M 選擇合適的搭配藥物。因此我們會走完整個研發旅程來證明這些,但我們正與 FDA 對話,目前沒有任何方式可以跳過第二期。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks Deborah. Tony?

    謝謝 Deborah。Tony?

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Sachin. Look, as you'll appreciate, only a small number of people inside GSK has seen the KALM-1 data, and we'll update you all when the KALM-2 data is in-house. It's on track. We have last patient last visit has already occurred. So we're very much on track of publication around the middle of the year, as I've indicated. And perhaps just a reminder for everyone here again, 15% to 20% reduction relative to placebo in Phase III at 24 weeks will be seen significant.

    Sachin。如你所理解,GSK 內部只有少數人看過 KALM-1 的數據;等 KALM-2 的數據在內部到位後,我們會向各位更新。目前進度如期。最後一位受試者的最後一次回診已經完成。所以我們非常有把握能如我所說,在年中左右發表。也再次提醒在座各位:在第三期、24 週時相對於安慰劑達到 15% 到 20% 的降低,將被視為顯著。

  • Operator

    Operator

  • Next question comes from Matthew Weston.

    下一個問題來自 Matthew Weston。

  • Unidentified Participant

    Unidentified Participant

  • It's actually a follow-on to Sachin's secret second question. Deborah, in your opening comments, you expect confidence in the long-acting six-month treatment regime on the market by the end of the decade. But given that we haven't yet achieved six months IM dosing for VH184, I have to be honest and say we're struggling to get to that timeline. Sach asked if you could accelerate it and you said no. So can you walk through the steps for development that gives you the confidence in being there at the end of the decade?

    其實是延續 Sachin 那個「秘密的第二個問題」。Deborah,你在開場評論中提到,你預期在本十年末能讓長效、六個月一次的治療方案上市。但鑑於我們尚未讓 VH184 達到每六個月一次的肌肉注射(IM)給藥,坦白說,我們很難理解如何能達到那個時程。Sach 問能否加速,你說不行。所以你能否說明一下研發的步驟,讓你有信心能在本十年末達成?

  • Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

    Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

  • So we've got a Phase II program, which has already started for VH184 because I think what people sometimes think is when we present the data at CROI, that's where we are in the process. We've already started the Phase IIa, which is the oral step we need to go through with VH184. We're expecting the VH-499 Phase II to start in the second half of the year. And then basically, we would be starting the Phase III, which we are in dialogue with regulators over as well as our Phase II program in 2028, and that allows us then to generate the data that will give us an end-of-decade launch.

    我們已經啟動了 VH184 的第二期計畫;因為我想有時候大家會以為我們在 CROI 發表數據時,才是我們所處的進度。我們其實已經開始了第二期 a(Phase IIa),也就是 VH184 必須走過的口服步驟。我們預期 VH-499 的第二期會在下半年啟動。接著基本上,我們會在 2028 年啟動第三期;我們也正就此與監管機關對話,同時也在推進並確認第二期計畫,這樣就能產出支持本十年末上市所需的數據。

  • So that's how everything is set out at the moment. Obviously, you talk to the regulators every step of the way as you design your clinical trials, you agree the endpoints and then you move on to the next stage. So as we stand here today, the dialogue that we have had with the regulators, the Phase II program that we are in the process of agreeing and our proposed Phase III would lead us to an end of 2030 approval.

    目前整體規劃就是這樣。當然,在你設計臨床試驗時,每一步都會與監管機關溝通,確認終點指標,然後再進入下一階段。所以以我們今天所處的位置來看,基於我們與監管機關的對話、我們正在協議中的第二期計畫,以及我們提出的第三期設計,將可使我們在 2030 年底獲得核准。

  • Operator

    Operator

  • Next question comes from Peter Verdult.

    下一個問題來自 Peter Verdult。

  • Peter Verdult - Analyst

    Peter Verdult - Analyst

  • Yeah, Pete here from BNP. Just one question, just a follow-up. On Bepi ahead of EASL. In fact, there's a massive disconnect between your ambitions in terms of commercial ambitions for the product. And I think consensus, which only had a couple of hundred million baked in. I realize we cannot go into any B-Well details, but I would like to understand how GSK thinks about getting surface antigen testing parcel standard practice. Feedback tells us this is really done presently. And then in terms of the checks that we've done with the community, they seem to be pointing to a functional cure rate near as 25% for (inaudible) the element across community to be really high. I know it could be static, I know between 15% to 20%, but -- and then you're willing to send on testing on what is clinically meaningful from the docs you speak to as we await [your] data?

    是的,我是 BNP 的 Pete。只有一個問題,算是追問。關於 EASL 之前的 Bepi。事實上,你們對該產品的商業企圖心與市場預期之間存在很大的落差。我認為市場共識只把幾億美元的收入納入模型。我知道我們不能深入任何 B-Well 的細節,但我想了解 GSK 如何看待讓表面抗原(HBsAg)檢測成為常規標準作法。回饋告訴我們,目前這件事其實做得並不普遍。另外,就我們與社群所做的查核而言,他們似乎指出(聽不清)在社群中的功能性治癒率接近 25%,而且社群對此要素的期待非常高。我知道這可能是靜態的,我也知道你們提到的是 15% 到 20%,但是——在我們等待你們數據之際,你能否分享一下,從你們所接觸的醫師角度,對「臨床上有意義」的治癒率與檢測推動,你們願意提供哪些看法?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Sure. No, it's Peter. I think it's very fair questions. I mean structurally, we've seen this in multiple disease areas. If there's no solution. There's no point looking for the problem. So many of these patients, if you look at the US diagnosis rates (inaudible) 1.2, I said before, only 500,000 are diagnosed in Europe to a similar ratio. Japan is probably the best of all of them. But our expectation is and the feedback that we've got is that once you've got the accessible treatment option, it is a downstream consequences of this infection are deeply unpleasant for the individual and the healthcare system. We expect that testing to increase. I don't know if you wanted to add any of the work that you guys have done to assess this or any other insights?

    當然。不,是 Peter。我認為這些都是非常合理的問題。我的意思是,從結構上來看,我們在多個疾病領域都看過這種情況。如果沒有解決方案,就沒有必要去找問題。這麼多患者,如果你看美國的診斷率(聽不清)1.2,我之前說過,歐洲只有 50 萬人被診斷出來,比例也差不多。日本可能是所有地區中做得最好的。但我們的預期以及我們收到的回饋是,一旦有可及的治療選項,這種感染的下游後果對個人與醫療體系都非常不愉快。我們預期檢測會增加。我不知道你是否想補充你們為評估這點所做的工作或任何其他見解?

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Yeah. And Peter, I'm not surprised. This is a new in a way, new approach in treatment of Hepatitis B. So a lot of these things are obviously very known to us as barriers like antigen surface testing like diagnosis. And we will -- we are going into that very -- with eyes wide open, aware of that. But what is very obvious is that there are reasons why people are -- want to be treated. It's a reduction of hepatocellular carcinoma, first thing. The other one, just stigma of hepatitis B, and that comes with available options for treatment that are lifelong. And patients or physicians are not very keen on lifelong treatment. That's a big, big motivator to change.

    是的。Peter,我並不意外。這在某種程度上是乙型肝炎治療的一種新方法。因此,像表面抗原檢測、診斷等這些障礙,對我們來說顯然都非常熟悉。而我們會——我們會非常——以充分認知、睜大眼睛地進入這個領域,清楚知道這些問題。但非常明顯的是,人們之所以——想要接受治療是有原因的。第一個是降低肝細胞癌的風險。另一個是乙肝的汙名化,而這又與現有可用的、需要終身治療的選項相關。而患者或醫師都不太願意接受終身治療。這是促使改變的一個非常、非常大的動力。

  • Testing will -- is available. It's just not used because it doesn't help with anything. It doesn't guide current treatment. It's not required for initiation of treatment. As soon as there are options that are requiring testing, we believe that is going to increase.

    檢測——是可用的。只是沒有被使用,因為它對任何事情都沒有幫助。它不會指導目前的治療。它也不是啟動治療所必需的。一旦有需要檢測的治療選項出現,我們相信使用量就會增加。

  • And just the last one. I think we need to -- we just need to remind ourselves. Reduction of DNA at the moment is the standard, which is followed in practice. For patients who have reduced DNA and who have also reduced antigen level expression, their risk of hepatocellular carcinoma is dropping by over 70%, close to 80%. So it's a very significant driver of medical value and benefit and that's what we see in the initial conversations with the regulators.

    再補充最後一點。我認為我們需要——我們只需要提醒自己。目前降低 DNA 是標準,而且在實務上也是依此執行。對於 DNA 已降低、且表面抗原表達水準也降低的患者,他們罹患肝細胞癌的風險會下降超過 70%,接近 80%。因此,這是醫療價值與效益非常重要的驅動因素,而這也是我們在與監管機構初步對話中所看到的。

  • As you can see, we have SENKU designation in Japan. We have breakthrough designation in the US. It is very much recognized by the healthcare authorities. We are going into this into what is new way of treating this disease. And I think you need to allow us also a certain level of -- well, uncertainty how this is -- how quickly this is going to be realized. But definitely, the value of the drug is very clearly recognized.

    如你所見,我們在日本獲得 SENKU 認定。我們在美國獲得突破性療法認定。這點已非常明確地被醫療主管機關所認可。我們正以一種新的方式來治療這個疾病。我想你也需要允許我們在——嗯——對於這將如何、以及會多快實現,保留一定程度的不確定性。但可以肯定的是,這個藥物的價值已被非常清楚地認可。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • And then just a reminder on functional cure rates because as Nina mentioned, the current broadly used approaches, nucleoside nucleotide therapy for which the combination of DNA and surface antigen reduction for functional is less than 2% for a lifelong therapy. And if you look at pegylated interferon, here, as you know, I mean it's 12 months of treatment and flu like symptoms for between 2% to 4% resolution. In China, experts would stay at slightly higher but heavy burden other patients. So as Nina said, we're being very thoughtful about this. And -- but there's a high commitment to this asset. And I think we've got something that will get experts attention at EASL. So let's see.

    另外再提醒一下功能性治癒率,因為如 Nina 提到,目前廣泛使用的方法——核苷(酸)類治療——其 DNA 與表面抗原降低所帶來的功能性治癒率,在終身治療下仍低於 2%。而如果你看聚乙二醇化干擾素,如你所知,治療 12 個月,會有類流感症狀,但緩解率只有 2% 到 4%。在中國,專家可能會說稍微高一些,但對其他患者而言負擔很重。所以如 Nina 所說,我們在這方面非常審慎。而且——我們對這項資產有高度承諾。我認為我們有一些東西會在 EASL 引起專家的注意。所以我們拭目以待。

  • Operator

    Operator

  • Next question comes from James Gordon.

    下一個問題來自 James Gordon。

  • James Gordon - Equity Analyst

    James Gordon - Equity Analyst

  • James Gordon from Barclays. The question was about extensive. So the early launch progress. I know it's early. And whether you are seeing any switching from existing more frequent [IR5s] and that is the NIMBLE extensive switch trial that showed the extensive inferiority [new color]. So does that mean it's harder to get switches? Or are you still seeing some people do a switch? And just what do you think this launch will look like once you get the J-code, I can see how that can hold you back in there -- but then once you got the J-code, it still be quite slow and steady because you're only then really going for the incident, not like the people already on biologics, if you're not switching?

    我是 Barclays 的 James Gordon。問題是關於 extensive。也就是早期上市推進的進展。我知道現在還早。以及你們是否看到有人從現有更高頻率的 [IR5s] 轉換用藥——也就是 NIMBLE 的 extensive 轉換試驗顯示 extensive 劣效[new color]。那這是否代表更難促成轉換?還是你們仍然看到有些人會轉換?另外,一旦你們拿到 J-code,你認為這次上市會是什麼樣子?我可以理解這會在當下拖慢你們——但拿到 J-code 之後,是否仍會相當緩慢且穩健,因為如果你們不做轉換,你們真正鎖定的就只是新發患者,而不是已經在用生物製劑的人?

  • And if I could squeeze in a follow-up because a few people did. Just on camlipixant, I had the comment on 15% to 20% benefit of Phase III being significant. But I think the Phase II was about twice as good as that. So why wouldn't it be so much lower? And isn't the 15% to 20% pretty similar to what Merck had with their P2X3 but ultimately, there's some differences. But ultimately, that wasn't approved by the FDA with about 15% to 20% benefit.

    如果我可以再塞一個追問,因為有幾個人也提到。關於 camlipixant,我聽到你提到第三期有 15% 到 20% 的效益是顯著的。但我記得第二期大概是那個的兩倍。那為什麼第三期不會低這麼多?而且 15% 到 20% 是否跟 Merck 的 P2X3 的結果很像,但最終有一些差異。但歸根結底,那個在大約 15% 到 20% 的效益下並沒有獲得 FDA 核准。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • James, I'll answer the second question super quickly. So I think the key thing is duration of effect and also the placebo adjusted that's the operative term. And the element with Merck's product really was the off-target effect, in fact, is a much more promiscuously binding molecule, in terms of addressing the receptors of P3X3, which are present in the part. And so you get this taste to serve [discurly], which unblinded the product and also limited their dose selection.

    James,我很快回答第二個問題。我認為關鍵在於效果持續時間,以及安慰劑校正(placebo adjusted)——這是關鍵用語。而 Merck 產品的問題其實是離靶效應;事實上它是一個結合更不具選擇性(promiscuously binding)的分子,就其作用於 P3X3 受體而言,而這些受體存在於——(聽不清)。因此你會出現這種味覺——(聽不清),這使得試驗被揭盲,也限制了他們的劑量選擇。

  • So you had higher, higher disturbance, toxicity, and lower efficacy plus some regulatory issues around cost monitoring. So I think we're talking apples and pears there, but we've taken those lessons and integrated them into not only the assessment of the clinical program, and we're looking forward to getting those results.

    所以你會看到更高、更高的干擾、毒性,以及更低的療效,外加一些關於成本監測的監管問題。因此我認為這是拿蘋果比梨,但我們已吸取那些教訓,並把它們整合到不僅是臨床計畫的評估中,我們也期待取得那些結果。

  • Tony, do you want to go through NIMBLE, Nina then go through where we are commercially with the launch? And then I'm happy to add anything else.

    Tony,你要不要先講一下 NIMBLE,然後 Nina 再講一下我們在商業端的上市進展?之後我也很樂意再補充其他內容。

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Yes. So let me just, first of all, a little bit about NIMBLE and its design. It was a non-registrational study. So not a filing requirement. And what's important to understand about the population in NIMBLE is they were very well controlled. So the general exacerbation rate was low.

    好的。那我先簡單說一下 NIMBLE 及其設計。這是一項非註冊性研究。所以不是申報所必需的。而理解 NIMBLE 受試族群很重要的一點是,他們的控制狀況非常好。因此整體惡化率很低。

  • It was not designed to make comparisons across switch in the various arms. And in fact, if I allow that comparison to be made, the absolute -- sorry, the difference in exacerbation rates was 0.08 per year. If that implies in a patient on therapy would need 12.5 years to realize a single additional exacerbation. You put that into the context of the benefits of compliance that's associated with the longer-acting agents, as Nina answered earlier, I think you have the importance of [fam] depemokimab as a long-acting agent in that population. I won't go any further on that, but the study was not designed to draw the conclusion that you have, James.

    它的設計並不是為了在各個治療組之間的切換進行比較。而且事實上,如果我允許進行那樣的比較,絕對值——抱歉,急性惡化率的差異是每年 0.08。這表示對於一位正在接受治療的病人,可能需要 12.5 年才會多出一次額外的急性惡化。把這點放在與長效藥物相關的依從性(如 Nina 先前回答所提)所帶來的益處背景下來看,我認為你就能理解 [fam] depemokimab 作為該族群長效藥物的重要性。我不再就此延伸,但這項研究並非為了得出你所提出的結論,James。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Tony. Nina?

    謝謝,Tony。Nina?

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Yeah. Just to add. So at the moment, the number of patients that are initiating actually, about 70% of them are coming from other biologics. In terms of the question, and obviously, we want a majority of the patients to be bio-naive. Just your question about, are we looking at just the incidents, remember, only about 30% of patients are on biologic. There is actually way more patients who are bionaive than those who are bioexposed. So there is a significant pool of patients who are available.

    是的。補充一下。目前,實際上開始使用治療的病人中,大約 70% 是從其他生物製劑轉換而來。就這個問題而言,當然,我們希望大多數病人是未曾使用過生物製劑(bio-naive)。至於你問我們是否只看新發個案,請記得,目前只有約 30% 的病人在使用生物製劑。實際上,未曾使用過生物製劑的病人遠多於曾使用過的病人。因此,可觸及的病人池相當可觀。

  • In terms of access and J-code, this is a therapy area where J-code is very relevant. We -- is going to unlock vast majority of the market, at the moment, only about 20% of the commercial patients in the US have access. And this is very normal in this therapy area, J-code is really a significant barrier initially and then it opens the opportunity as the J-code becomes available.

    就可近性與 J-code 而言,這是一個 J-code 非常關鍵的治療領域。我們——它將解鎖市場的絕大多數;目前在美國,只有約 20% 的商業保險病人能夠取得用藥。而這在此治療領域非常常見:一開始 J-code 確實是重大障礙,之後隨著 J-code 可用,就會打開機會。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yeah. And James, I'll just add some other market research, which I think is quite encouraging. So if you look at who's prescribing at this point, about 57% of the patients prescribed by pulmonologist, about 23% by allergists, which is in line with what we expected. Unaided awareness is ahead of benchmarks. And the intent to use is nicely a benchmark. And the main driver is questions around access, which is what we expect particularly when you're buying a six-monthly treatment. So we've got that approach. But obviously, the ungating factor is the J-code.

    是的。James,我再補充一些市場調研結果,我覺得相當令人鼓舞。如果你看目前是誰在開立處方,大約 57% 的病人由肺科醫師開立,約 23% 由過敏專科醫師開立,這與我們的預期一致。未提示知名度(unaided awareness)高於基準。而使用意願(intent to use)也很好地達到基準。主要驅動因素是對可近性的疑慮,這正如我們所預期,特別是當你要採購一個每六個月一次的治療時。所以我們已經有相應的做法。但顯然,解除限制的關鍵因素是 J-code。

  • And actually, if you look at the Q2, faith and belief in terms of sustained suppression of the key Q2 drivers. This is beyond other biologics at this point. So we're quietly assembling the pieces which will drive usage of this product but very similar to Blenrep, I think we need to wait until we're into the second quarter before we can give you the full picture. Also, we've just started launch in Japan. I was here the other day, very good traction. And Germany was also there the other day, and they've got good traction and good start already. So I would say we just need to keep watching this space and stay focused.

    而且實際上,如果你看第二季(Q2),在關鍵 Q2 驅動因素上,對於關鍵指標能否持續抑制的信心與信念。在這個時間點,這已經優於其他生物製劑。所以我們正在低調地把將推動這個產品使用的各個拼圖逐步拼起來;但非常類似於 Blenrep,我認為我們需要等到進入第二季之後,才能給你完整的全貌。另外,我們也才剛在日本啟動上市。我前幾天在那裡,進展非常好。德國那邊我前幾天也在,已經有不錯的動能與良好的起步。所以我會說,我們只需要持續觀察這個領域並保持專注。

  • Operator

    Operator

  • Next question comes from Sarita Kapila.

    下一個問題來自 Sarita Kapila。

  • Unidentified Participant

    Unidentified Participant

  • Recently, there was a change to the Florida ADAP. So Biktarvy access was removed and Desai was restricted. So how should we think about this change in the order signals for HIV reimbursement in the US? Is there any risk that we see similar changes elsewhere?

    最近佛羅里達州的 ADAP 有所變更。因此,Biktarvy 的可近性被移除,而 Desai 被限制。那麼,我們應該如何看待這項變更對美國 HIV 給付(reimbursement)訂單訊號的影響?是否有風險在其他地方也看到類似變更?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Sarita. Deborah?

    謝謝,Sarita。Deborah?

  • Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

    Deborah Waterhouse - Chief Executive Officer - ViiV Healthcare and President - GSK Global Health

  • Yes. So thanks for the question, Sarita. So ADAC is the SafetyNet program for people who are living with HIV who do not have insurance. And because states are strapped for cash, they are looking at ways to save money on ADAC. And what Florida did was two things. They reduced the threshold by which you were able to access ADAC and they restricted Biktarvy and Descovy.

    好的。謝謝你的問題,Sarita。ADAC 是針對沒有保險、與 HIV 共存者的安全網(SafetyNet)計畫。由於各州財政吃緊,他們正在尋找在 ADAC 上節省支出的方式。佛羅里達州做了兩件事。他們降低了可取得 ADAC 的門檻,並且限制了 Biktarvy 與 Descovy。

  • There was a court case brought immediately by community around the threshold of which you can enter ADAC and they weren't, so it went back to being 400% of the property threshold versus 150%. So that was reversed, but there isn't the opportunity and there always has been actually to tighten the formulary. And that is currently taking place in Florida, and we've seen people switching off Descovy and Biktarvy to other medicines.

    社群立即就可進入 ADAC 的門檻提起訴訟,而他們並未成功,因此門檻回到以貧困門檻(property threshold)的 400% 為準,而不是 150%。所以這一點被撤回了;但在收緊處方集(formulary)方面,確實沒有阻礙,而且其實一直以來都存在這樣的空間。目前佛羅里達州正在發生這種情況,我們也看到有人從 Descovy 與 Biktarvy 轉換到其他藥物。

  • Obviously, Dovato and Cabenuva as well. So I think this is an area of focus as it has been for a while. I think the court case that was brought immediately by the community was very helpful because the threshold of when you can benefit from ADAC was not successfully reduced. But I think we should expect other states to look at ADAC and to make sure that it's being run efficiently and effectively.

    當然也包括 Dovato 和 Cabenuva。所以我認為這一直是、且已經有一段時間是我們關注的重點。我認為社群立即提起的訴訟非常有幫助,因為 ADAC 受益門檻並未被成功下調。但我認為我們應該預期其他州也會檢視 ADAC,並確保其運作有效率且有效果。

  • But overall, I don't think you're going to see a reduction. I think you -- what you might see is some changes to formulary. But as we know, it's very guideline-driven therapy area, the community are now pushing back at the restriction of Descovy and Biktarvy. So that may in its own right end up being reversed. But at the moment, that is still in place.

    但整體而言,我不認為你會看到給付縮減。我認為你——你可能會看到的是處方集的一些調整。但如我們所知,這是一個高度依循治療指引的治療領域,社群目前也在對 Descovy 與 Biktarvy 的限制提出反對。因此,這本身也可能最終被撤回。但目前,該限制仍然存在。

  • Operator

    Operator

  • Next question comes from Michael Leuchten.

    下一個問題來自 Michael Leuchten。

  • Unidentified Participant

    Unidentified Participant

  • If I could please just go back to the Q2 business update. Just trying to understand, is this meant to be a comprehensive review, both top-line and bottom-line trajectory? Or is it meant to be a portfolio update around the pipeline, including these, please?

    如果可以的話,我想回到第二季(Q2)的業務更新。我想了解,這是否意味著一個全面性的回顧,涵蓋營收端與獲利端的走勢?還是說,這是針對產品組合與研發管線的更新,包括這些內容?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Michael, the latter. I mean, we've found in the past when we do meet the management events as standalone, they're useful to get granularity. But the portfolio has becoming broad enough and complex enough. We thought it would be helpful for you and shareholders for us to step you through why we sound enthusiastic. And what we've been doing with our time over the last few months in terms of accelerating those assets. So that's the intent. And to give just greater granularity in more depth on the data.

    謝謝,Michael,是後者。我的意思是,我們過去發現,當我們把管理層活動作為獨立場次來進行時,對於取得更細緻的資訊很有幫助。但目前產品組合已經變得足夠廣泛且足夠複雜。我們認為,對你以及股東而言,讓我們帶你逐步了解為什麼我們聽起來如此樂觀會很有幫助。以及過去幾個月我們在加速這些資產方面做了哪些工作、如何投入時間。這就是目的。並且就數據提供更高的細緻度與更深入的說明。

  • Operator

    Operator

  • Next question comes from Simon Baker.

    下一個問題來自 Simon Baker。

  • Unidentified Participant

    Unidentified Participant

  • A slightly broader one. Just going back to one of your opening comments, Luke. You talked about accelerating pipeline delivery. I wonder if you could just dig down and give us a little bit more color on that. Is that about changing decision-making processes now? Or is it about changing development practice and trial design going forward? So just some color on what that phrase means in reality would be great.

    這是一個稍微更宏觀的問題。回到你開場的一個評論,Luke。你提到要加速研發管線的交付。我想知道你是否可以再深入一點,給我們更多細節。這是指現在要改變決策流程嗎?還是指未來要改變開發實務與試驗設計?所以,如果能就這句話在實務上到底代表什麼提供一些說明,會很棒。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes, sure, Simon. And we've made damn sure I touch any statement to something that we're actually doing in practice, so be short of that. What does that look like? So every two weeks, Tony, Nina, and myself, Monde, and Deborah, if it's HIV with David, we look through all the clinical execution, look at what studies are on track, which are not. And then it may trigger any discussion around the protocol design, the execution on the ground, the meeting then may pivot to some life-cycle opportunities that we've got, if Julie has found some money under the bed, that we can accelerate those programs and the economic justification and the clinical justification for doing that.

    是的,當然,Simon。而且我們非常確定,我所提到的任何說法都必須對應到我們實際正在做的事情,所以就不多說空話。那看起來是什麼樣子?所以每兩週,Tony、Nina、我本人、Monde,以及 Deborah(如果是 HIV 的話則與 David 一起),我們會把所有臨床執行狀況過一遍,看看哪些研究按計畫進行、哪些沒有。接著這可能會引發對試驗方案設計、現場執行的討論;會議也可能轉向我們掌握的一些產品生命週期機會——如果 Julie 在床底下找到一些錢——我們就能加速那些計畫,以及這麼做在經濟面與臨床面的正當性。

  • So very dynamically managing the portfolio. But again, we're not writing e-mails to each other and 10 lines of management. It's us interacting directly with the team leaders who are managing those programs and looking at them in the eyes and they get to look us in the eyes about what -- where the program is at, what's going right, what's not going right and how do we fix it. Or if there's an opportunity, how do we exploit that without having to sort of at only endless meetings to discuss that.

    所以我們是以非常動態的方式在管理投資組合。但同樣地,我們不是彼此寫電子郵件、搞十行字的管理。而是我們直接與負責管理這些專案的團隊領導互動,面對面看著他們,他們也能看著我們,坦白說明——專案目前在哪裡、哪些進展順利、哪些不順利,以及我們要怎麼修正。或者如果有機會,我們要如何把握,而不必靠無止盡的會議來討論。

  • So out of that, we're creating a more aggressive culture in terms of pursuing opportunities, but also one that people have to back up in what they're doing with the facts or at least a logical explanation scientifically, clinically, why that may be a decision to make. And then we want to gain the level of risk we're taking. So it's really everything that you're saying. But the core focus is I strongly -- and you guys know this better than me. I strongly believe the way that we're going to create value is to accelerate what we have in the late-stage portfolio and get it to patients faster in a more broad fashion if there are opportunities for life-cycle management and then translate that into faster top-line growth and commercial success. So if we do that, we should be creating value for our shareholders.

    因此,我們正在建立一種更積極追求機會的文化,但同時也要求大家:你在做的事情必須用事實來支撐,或至少在科學與臨床上提供合乎邏輯的解釋,說明為什麼這可能是該做的決策。然後我們也希望掌握我們正在承擔的風險程度。所以基本上就是你所說的那些。但核心重點是——我非常——而你們其實比我更清楚。我堅信我們創造價值的方式,是加速我們後期研發組合中的資產,讓它們更快、更廣泛地到達病患;若有生命週期管理的機會,就把握住,並把這轉化為更快的營收成長與商業成功。如果我們做到這些,就應該能為股東創造價值。

  • So that's how it works. We also have other ways, again, to redirect resources. And if we see something not working, we either fix it or take the resources away and give them to someone else. So it's a Darwinian process, and it's designed to transparently create value.

    所以運作方式就是這樣。我們也有其他方式可以重新配置資源。如果我們看到某件事行不通,我們要嘛把它修好,要嘛把資源抽走,交給其他人。所以這是一個達爾文式的過程,目的在於以透明的方式創造價值。

  • Operator

    Operator

  • Next question comes from Steve Scala.

    下一個問題來自 Steve Scala。

  • Unidentified Participant

    Unidentified Participant

  • A question on Shingrix with three brief parts. First, can you quantify the magnitude of US inventory stocking? Second, are things improving in China. And thirdly, it seems like you're all in on dementia starting a 34,000 patient trial after being cautious for a long time. Is that how to read it?

    關於 Shingrix 的問題,有三個簡短部分。第一,你們能量化美國通路庫存補貨的幅度嗎?第二,中國的情況是否在改善?第三,看起來你們在失智症上是全力投入——在長期謹慎之後,啟動一項 34,000 名病患的試驗。可以這樣解讀嗎?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Right. Thanks. So I'll answer the inventory one pretty quickly, and then maybe, Nina, if you wanted to take China. I mean if you look at the US, the IV right now is around 45%. So that's up 3.5 points versus same time last year, which is in the range that we gave you of two to four patient points each year.

    好的。謝謝。我先很快回答庫存的部分,然後 Nina,如果你願意的話可以談談中國。我的意思是,如果你看美國,目前 IV 大約是 45%。所以相較去年同期上升了 3.5 個百分點,落在我們先前給你們的每年增加 2 到 4 個病患百分點的區間內。

  • If you look at the remaining are, there's about 70 million people above 50 who remain unvaccinated. About a third of them have intent to get vaccinated, that's material based on the market research. But again, we're concentrating on the comorbid stock population that are more motivated and their doctors and pharmacists will motivate it to do that. All the market research on pharmacists and doctors is stable.

    如果你看剩餘的部分,仍有大約 7,000 萬名 50 歲以上的人尚未接種。其中約三分之一有接種意願,這在市場研究上是相當可觀的。但同樣地,我們聚焦在有共病的存量族群,他們動機更強,而他們的醫師與藥師也會推動他們去接種。所有關於藥師與醫師的市場研究都很穩定。

  • In Q1, (inauidble) was the number one priority for pharmacists to vaccinate, which is the same as last year. before we get to the flu season. In terms of stocking, we did launch the PFS to fully liquid in '26. It's easier for pharmacists, we don't factor any demand increase because of that, but it's just easier for the pharmacists to employ it.

    在第一季,(聽不清)是藥師最優先要施打的疫苗,這和去年一樣,在進入流感季之前。就備貨而言,我們確實推出了 PFS,並在 26 年全面轉為液體劑型。這對藥師來說更容易使用;我們不會因為這點而把需求增加納入假設,但它確實讓藥師更容易操作。

  • The wholesalers were pretty steady. So Q1 '26 0.6 million doses. If you look at the end of last year, it was 0.5. If you look at the same time last year, it was 0.4. So very much in the typical range. There is some increase in retail inventory -- so -- and that's associated with the PFS.

    批發商端相當穩定。所以 26 年第一季是 60 萬劑。如果你看去年底是 50 萬;去年同期是 40 萬。所以非常符合典型區間。零售端庫存確實有一些增加——而這與 PFS 有關。

  • So it was 2.4 million. If you look at same time last year, it was 1.7 million doses at the end of 2025, which is not necessarily a fair comparator of the flu season, 1.4 million. So stocking has a component there, but we're also seeing reasonable underlying demand following the strategy of focusing on comorbid.

    所以是 240 萬劑。如果你看去年同期是 170 萬劑;而 2025 年底是 140 萬劑——這不一定是流感季的公平比較基準。所以備貨確實有一部分因素,但我們也看到在聚焦共病族群的策略下,基本面需求表現合理。

  • Nina, anything you wanted to add on US or China and then we'll go to Tony.

    Nina,你還想補充美國或中國的部分嗎?然後我們再交給 Tony。

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Yes. So just briefly on China. The number of doses administered to patients is increasing. So that's -- that demand is improving. You will not see that in the sales numbers because that's going out from the available stock at GSK, probably for this year, at least majority of this year, we would not see sales numbers changing on the GSK side as that stock is being reduced.

    是的。簡單談一下中國。實際施打到病患的劑量數正在增加。所以——需求正在改善。但你不會在銷售數字上看到這點,因為目前是從 GSK 既有可用庫存出貨;可能在今年、至少今年大部分時間,隨著庫存被消化,GSK 端的銷售數字不會出現變化。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Nina. So work in progress very much from China. Tony?

    謝謝,Nina。所以中國方面確實仍在進行中。Tony?

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Yes, Steve, on thin dementia, I would say this is just the latest in the plan we described that sits alongside those studies that we have running in the UK and now a pragmatic study in Finland to give you some details. This is dementia diagnosis. And as you said, around 30,000 individuals. It's Shingrix versus placebo study and the data capture is largely passed through a registry basis. So on a three-year follow-up, but I would look at it very much as just the next example in what will become a collection of studies that explore outcomes with Shingrix in both dementia and indeed outcomes that I'm doing in partnership with Mondo and the Med Affairs team.

    是的,Steve,關於失智症,我會說這只是我們所描述計畫中的最新一步;它與我們在英國進行中的那些研究並行,現在也在芬蘭有一項務實性研究,我提供一些細節。這是針對失智症診斷。如你所說,大約 30,000 名受試者。這是一項 Shingrix 對照安慰劑的研究,資料收集主要是透過登錄系統(registry)的方式。所以追蹤三年;但我會把它視為下一個例子:未來會形成一系列研究,探索 Shingrix 在失智症上的結果,並且也包括我與 Mondo 及醫學事務團隊合作所做的其他結果研究。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes, I would stress that Mace component, Steve. Next question, please. We have time for two more short questions, please.

    是的,Steve,我要強調那個 Mace 的組成部分。下一個問題,請。我們還有時間再問兩個簡短問題,請。

  • Operator

    Operator

  • Emmanuel Papadakis.

    Emmanuel Papadakis。

  • Unidentified Participant

    Unidentified Participant

  • Yeah, I'm tempted to ask Julie about the money under the bed, but I'll take one on Jemperli. Maybe you could talk a little bit about the softer Q1 relative to expectations after a pretty strong run of results. Particularly interested in how endometrial and rectal outlook is shaping up. I mean you do have Azo1 and 2 pending, but they're in the MRI setting and you already have a tumor-agnostic MSI label. So I would imagine they're going to have pretty limited impact. Is it going to be jaded in head and neck that really catalyze the next step up? And what's the sort of quantum of commercial opportunity there?

    是的,我很想問 Julie 那個床底下的錢,但我先問一個關於 Jemperli 的問題。你們能否談談第一季相對於預期較疲軟的原因?畢竟之前一段時間的結果表現相當強勁。我特別想了解子宮內膜癌與直腸癌的前景目前如何發展。我的意思是,你們確實有 Azo1 和 2 即將出結果,但它們是在 MRI 的情境下,而且你們已經有腫瘤不可知(tumor-agnostic)的 MSI 適應症標籤。所以我想它們的影響應該相當有限。接下來真正推動下一階段成長的,會是頭頸癌那邊嗎?那邊的商業機會量級大概是多少?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Great. Thanks, Emmanuel Nina, you want to cover?

    很好。謝謝,Emmanuel。Nina,你要補充嗎?

  • Nina Mojas - President - Global Product Strategy

    Nina Mojas - President - Global Product Strategy

  • Yeah, I think we have talked about this before. We -- of the GBP2 billion that we have communicated externally for Jemperli for endometrial cancer is about GBP1 billion and then colorectal and head and neck is the -- we see it as another GBP1 billion. And at the moment, we are on track for that.

    是的,我想我們之前談過這個。我們——我們對外溝通的 Jemperli 在子宮內膜癌的 20 億英鎊規模中,大約 10 億英鎊來自子宮內膜癌,然後結直腸癌以及頭頸癌——我們把它視為另外 10 億英鎊。而目前,我們正按計畫推進。

  • So one is going to read out later this year, very high belief and confidence that, that's a positive study as we have seen already. So -- and then it's to obviously significantly higher opportunity and head and neck definitely.

    所以其中一項研究會在今年稍晚讀出,我們非常相信且有信心那會是正面的研究結果,正如我們已經看到的。所以——然後顯然還有顯著更高的機會,頭頸癌肯定也是。

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Yes. Emmanuel, we've still got a lot to do operationally in the US in terms of endometrial. You look at the stats, about 60% of oncologists just used KEYTRUDA despite the overall survival. So we've got area to target those individuals, and we do have the market research that a physician can recycle survival benefit there a lot more likely, obviously, to use Jemperli. So again, we remain very committed to this product and I look forward to updating you as we get those readouts.

    是的。Emmanuel,就子宮內膜癌而言,我們在美國的營運層面仍有很多工作要做。你看那些統計數據,大約 60% 的腫瘤科醫師仍然只使用 KEYTRUDA,儘管已有整體存活期(OS)數據。所以我們有空間去鎖定那些醫師;而且我們也有市場調研顯示,若醫師能再次確認那裡的存活獲益,他們顯然更可能使用 Jemperli。因此,我們依然非常致力於這個產品,也期待在取得那些讀出結果時向你更新。

  • Tony Wood - Chief Scientific Officer

    Tony Wood - Chief Scientific Officer

  • Just a complete picture as well we have a chemo-free study in EC, which we'll have data this year as well as we're looking to expand the population there, too, right?

    另外補充完整圖像:我們在子宮內膜癌(EC)也有一項無化療研究,今年也會有數據,同時我們也在尋求擴大那裡的族群,對吧?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Last question, correct?

    最後一個問題,對嗎?

  • Operator

    Operator

  • Last question comes from Seamus.

    最後一個問題來自 Seamus。

  • Unidentified Participant

    Unidentified Participant

  • So just quickly wanted to get a sense on NUCALA and the uptake there. Where are you seeing the emergence of sort of broader utilization and how do you feel that actually positions Exdensur over time in that opportunity?

    我想快速了解一下 NUCALA 的採用情況與滲透。你們在哪些地方看到更廣泛使用的趨勢出現?以及你們覺得這如何在時間推移下,讓 Exdensur 在那個機會中取得更好的定位?

  • Luke Miels - Chief Executive Officer, Executive Director

    Luke Miels - Chief Executive Officer, Executive Director

  • Thanks, Seamus. So if you look at the growth of NUCALA in the US about 50% of that volume is from COPD. Globally, it's about one-third. And then you've got EGPA, HCS, and other indications with NUCALA more broadly.

    謝謝你,Seamus。如果你看 NUCALA 在美國的成長,大約 50% 的量來自 COPD。在全球,大約是三分之一。另外還有 EGPA、HCS,以及其他更廣泛的 NUCALA 適應症。

  • But as we launch Exdensur, we take the resources of NUCALA excluding COPD. So we have a team in the US who's still promoting COPD and doing quite well, as you can see. But all of the other indications are no longer promoted. We're 100% committed to Exdensur. And that's the strategy.

    但當我們推出 Exdensur 時,我們會把 NUCALA 的資源(不含 COPD)轉移過來。所以我們在美國仍有一個團隊持續推廣 COPD,而且如你所見表現相當不錯。但其他所有適應症就不再推廣。我們對 Exdensur 是 100% 投入。這就是策略。

  • And I'll just come back to the relative volatility of these patient populations, which I think surprises everyone, and creates a degree of chain that we're looking to exploit with Exdensur.

    我也想再回到這些病患族群相對波動性的議題;我認為這讓所有人都感到意外,並形成某種我們希望透過 Exdensur 加以利用的連鎖效應。

  • So great. I'll stop to hopefully answer your question, Seamus. If I didn't, I'm happy to follow up offline. Thanks, everyone. Appreciate your interest in the company, and I hope the questions and answer session was useful. Thank you.

    很好。我先停在這裡,希望已回答你的問題,Seamus。如果沒有,我很樂意會後再跟進。謝謝大家。感謝各位對公司的關注,也希望這場問答環節對大家有幫助。謝謝。